Combination of a TA-MUC1-targeting antibody and an EGFR-targeting antibody is safe and feasible. Interesting antitumor activity was observed in heavily pretreated patients. Future studies should test this combination together with chemotherapy and explore the potential of sTA-MUC1 as a companion biomarker for further development of the combination.
Combination of TA-MUC1 and EGFR targeting antibody is safe and feasible . Interesting anti-tumor activity was observed in heavily pretreated CRC and NSCLC patients . Levels of soluble TA-MUC1 may have predictive value and potentially be a companion biomarker for further development of the combination